10x Genomics Stock Alpha and Beta Analysis
| TXG Stock | USD 16.47 0.57 3.58% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as 10X Genomics. It also helps investors analyze the systematic and unsystematic risks associated with investing in 10X Genomics over a specified time horizon. Remember, high 10X Genomics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to 10X Genomics' market risk premium analysis include:
Beta 1.49 | Alpha (0.60) | Risk 4.57 | Sharpe Ratio (0.10) | Expected Return (0.46) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
10X |
10X Genomics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. 10X Genomics market risk premium is the additional return an investor will receive from holding 10X Genomics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in 10X Genomics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate 10X Genomics' performance over market.| α | -0.6 | β | 1.49 |
10X Genomics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of 10X Genomics' Buy-and-hold return. Our buy-and-hold chart shows how 10X Genomics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.10X Genomics Market Price Analysis
Market price analysis indicators help investors to evaluate how 10X Genomics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading 10X Genomics shares will generate the highest return on investment. By understating and applying 10X Genomics stock market price indicators, traders can identify 10X Genomics position entry and exit signals to maximize returns.
10X Genomics Return and Market Media
The median price of 10X Genomics for the period between Tue, Sep 3, 2024 and Mon, Dec 2, 2024 is 16.6 with a coefficient of variation of 18.77. The daily time series for the period is distributed with a sample standard deviation of 3.44, arithmetic mean of 18.33, and mean deviation of 3.23. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 1000 shares by Serge Saxonov of 10X Genomics at 49.5301 subject to Rule 16b-3 | 09/06/2024 |
2 | Disposition of 2961 shares by Justin McAnear of 10X Genomics at 22.5297 subject to Rule 16b-3 | 09/11/2024 |
3 | 10x Genomics Inc Shares Up 4.21 percent on Sep 13 | 09/13/2024 |
4 | Company News for Oct 11, 2024 | 10/11/2024 |
5 | 10x Genomics Inc Q3 2024 Earnings Call Highlights Navigating Challenges with Strategic ... | 10/30/2024 |
6 | UBS Group Issues Pessimistic Forecast for 10x Genomics Stock Price | 11/01/2024 |
7 | 10x Genomics to Present at the Wolfe Research 2024 Healthcare Conference | 11/07/2024 |
8 | Disposition of 534 shares by Serge Saxonov of 10X Genomics at 55.064 subject to Rule 16b-3 | 11/12/2024 |
9 | Sumitomo Mitsui Trust Group Inc. Has 143.91 Million Holdings in 10x Genomics, Inc. | 11/13/2024 |
10 | Baillie Gifford Co. Reduces Stock Holdings in 10x Genomics, Inc. | 11/14/2024 |
11 | 10x Genomics, Inc. Among the Best Genomics Stocks to Buy Right Now - Yahoo Finance | 11/19/2024 |
12 | Disposition of 1850 shares by Serge Saxonov of 10X Genomics subject to Rule 16b-3 | 11/21/2024 |
13 | Disposition of 5807 shares by Benjamin Hindson of 10X Genomics at 13.6878 subject to Rule 16b-3 | 11/22/2024 |
14 | 10x genomics chief scientific officer sells 79,485 in stock | 11/25/2024 |
About 10X Genomics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including 10X or other stocks. Alpha measures the amount that position in 10X Genomics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Payables Turnover | 4.27 | 5.57 | 13.31 | 13.97 | Days Of Inventory On Hand | 295.41 | 247.49 | 128.47 | 140.12 |
10X Genomics Upcoming Company Events
As portrayed in its financial statements, the presentation of 10X Genomics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, 10X Genomics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of 10X Genomics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of 10X Genomics. Please utilize our Beneish M Score to check the likelihood of 10X Genomics' management manipulating its earnings.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with 10X Genomics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out 10X Genomics Backtesting, 10X Genomics Valuation, 10X Genomics Correlation, 10X Genomics Hype Analysis, 10X Genomics Volatility, 10X Genomics History and analyze 10X Genomics Performance. For more detail on how to invest in 10X Stock please use our How to Invest in 10X Genomics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
10X Genomics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.